Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR — Clinical Trial Site

41 Registered trials

19 Currently recruiting

Organisation

Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR

Location

Nuertingen, Germany

Identifier

ORG-100040303

Address

Steinengrabenstrasse 17, 72622, Germany

Departments

#1802: Studienpraxis Urologie
2605
N/A
NA
not applicable
Praxis für Urologie
Private research practice
Studienpraxis fuer Urologie
Studienpraxis Urologie
Studienpraxis Urologie Nürtingen
Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR
Studienzentrum
Urologie
Urology
Uroncology

Clinical trials at this site (41)

Search interface

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Clear cell renal cell carcinoma (ccRCC, first-, second- 3 2023-01-09
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Bladder Cancer 5 2021-10-26
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended

2024-516481-11-00 Metastatic Castration-Resistant Prostate Cancer 5 2020-09-22
Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended

2023-504998-20-00 Metastatic Hormone-sensitive Prostate Cancer Characteri 5 2020-09-18
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Prostate Cancer 10 2019-01-04
Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos… Ended

2023-505341-23-00 Non-muscle invasive bladder cancer 5 2018-07-27
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Ended

2023-503919-15-00 Prostatic Neoplasms 3 2024-01-09
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended

2022-501078-20-00 Metastatic Castration-resistant Prostate Cancer 4 2023-05-15
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3… Ended

2022-501251-81-00 Renal cell carcinoma 5 2017-06-08
A Study Testing a New Drug (ALT-803) With BCG to Treat Early-Stage Bladder Cancer Ended

2025-521223-78-00 Non-Muscle Invasive Bladder Cancer 4